These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 27041692)
1. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692 [TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986 [TBL] [Abstract][Full Text] [Related]
3. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584 [TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
5. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
6. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715 [TBL] [Abstract][Full Text] [Related]
7. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673 [TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. Tuchman SA; Bacon WA; Huang LW; Long G; Rizzieri D; Horwitz M; Chute JP; Sullivan K; Morris Engemann A; Yopp A; Li Z; Corbet K; Chao N; Gasparetto C J Clin Apher; 2015 Jun; 30(3):176-82. PubMed ID: 25293363 [TBL] [Abstract][Full Text] [Related]
9. Impact of lenalidomide-based induction therapy on the mobilization of CD34 Partanen A; Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Putkonen M; Sankelo M; Pelkonen J; Mäntymaa P; Varmavuo V; Jantunen E Transfusion; 2017 Oct; 57(10):2366-2372. PubMed ID: 28681435 [TBL] [Abstract][Full Text] [Related]
10. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622 [TBL] [Abstract][Full Text] [Related]
11. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. Gazitt Y; Akay C; Thomas C Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673 [TBL] [Abstract][Full Text] [Related]
12. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059 [TBL] [Abstract][Full Text] [Related]
13. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097 [TBL] [Abstract][Full Text] [Related]
14. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. Sosman JA; Stiff P; Moss SM; Sorokin P; Martone B; Bayer R; van Besien K; Devine S; Stock W; Peace D; Chen Y; Long C; Gustin D; Viana M; Hoffman R J Clin Oncol; 2001 Feb; 19(3):634-44. PubMed ID: 11157013 [TBL] [Abstract][Full Text] [Related]
15. Comparison of CD34 Anu P; Antti T; Raija S; Marja P; Jaakko V; Timo S; Mervi P; Marja S; Anu S; Karri P; Taru K; Jukka P; Pentti M; Esa J; Ville V Transfusion; 2021 Nov; 61(11):3202-3212. PubMed ID: 34498764 [TBL] [Abstract][Full Text] [Related]
16. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498 [TBL] [Abstract][Full Text] [Related]
17. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718 [TBL] [Abstract][Full Text] [Related]
18. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Nazha A; Cook R; Vogl DT; Mangan PA; Gardler M; Hummel K; Cunningham K; Luger SM; Porter DL; Schuster S; O'Doherty U; Siegel D; Stadtmauer EA Bone Marrow Transplant; 2011 Jan; 46(1):59-63. PubMed ID: 20421869 [TBL] [Abstract][Full Text] [Related]
20. Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone. Benyamini N; Avivi I; Dann EJ; Zuckerman T; Lavi N; Katz T Ann Hematol; 2017 Mar; 96(3):461-467. PubMed ID: 28013359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]